Medical Licensing (MD/DO) · Independent exam preparation
EBDVD Specialist Preparation: 60 Clinical Reasoning Concepts Study Guide
Practise lesion interpretation, biopsy selection, STI testing, cancer staging and treatment safety across the five EBDVD specialist examination domains.
By CertMedbry · Updated 19 October 2026
Build decisions from morphology, mechanisms and evidence: choose diagnostic specimens, interpret STI results, stage cutaneous melanoma and recognise treatment hazards. This selective guide develops 60 concepts across the five examination sessions. The official examination outline and its linked European training curriculum define the full scope, including competencies beyond this selection.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and credential does this guide cover?
It covers the UEMS European Board of Dermatovenereology Diploma Examination, called EBDVD by the issuer. EBDV identifies the board and also appears in diploma labels; it does not establish a separate examination pathway. The assessment is a quality mark associated with specialist training. Passing does not independently grant national permission to practise.
UEMS European Board of Dermatovenereology Diploma Examination 2026
How many questions are there, and are pretest questions identified?
The published 2026 structure contains 200 MCQs, divided into five sessions of 40 questions. The scoring section describes one correct answer per question, one point for a correct response and zero for an incorrect response, without negative marking. No separate unscored or pretest allocation is identified.
UEMS European Board of Dermatovenereology Diploma Examination 2026
What duration, delivery method and item styles are verified?
The 2026 timetable assigns one hour to each of five sessions: five hours of answering time within one day, with scheduled breaks. Delivery is computer-based and online, in English, with on-site and approved remote arrangements. MCQs include a clinical slide collection and have one correct answer. The page does not describe adaptive testing. These text-based drills do not reproduce the slide component.
UEMS European Board of Dermatovenereology Diploma Examination 2026
How is the passing standard applied?
The issuer states a minimum passing score of 55% in each of the five sessions. Under the published 40-question session structure, that corresponds to 22 correct responses per session. A strong aggregate score does not replace meeting the stated standard in every session.
UEMS European Board of Dermatovenereology Diploma Examination 2026
Which blueprint and curriculum dates apply?
The examination page describes the 2026 examination and links training requirements approved on 21 October 2017, a date corroborated by the UEMS 2026.1 report. No separate syllabus effective date is stated. Each 20% domain allocation is calculated from 40 of 200 questions, rather than a separately published topic weight. The issuer permits changes to session questions and topics up to one month before the examination.
UEMS European Board of Dermatovenereology Diploma Examination 2026 · Training Requirements for the Specialty of Dermatology and Venereology · UEMS Body Report 2026.1
Does the older curriculum establish an oral examination requirement?
The 2017 training document discusses written and oral assessment in its broader training framework. The specific 2026 examination page describes five computer-based MCQ sessions and does not list an oral component. Use the examination-specific instructions for the sitting concerned.
UEMS European Board of Dermatovenereology Diploma Examination 2026 · Training Requirements for the Specialty of Dermatology and Venereology
How do specialist and resident applications differ?
Both application routes lead to the same evidenced examination. Specialists document recognised specialist registration; residents require confirmation of training from their programme leadership. The page repeatedly states completion of three residency years at application, but its resident document list also mentions four years. That internal inconsistency requires clarification from the examination manager before relying on eligibility.
UEMS European Board of Dermatovenereology Diploma Examination 2026
Is the listed 2026 date an upcoming examination?
The page lists 25 September 2026 and states that applications are closed. That date had already passed by 19 October 2026. No 2027 sitting is established by this announcement, so future dates and arrangements should be taken from a subsequent issuer announcement.
UEMS European Board of Dermatovenereology Diploma Examination 2026
How should European candidates use the clinical references?
The European curriculum establishes examination scope. Disease guidelines, government clinical references and prescribing information support the clinical teaching. CDC material supplies clearly identified diagnostic principles; its staging conventions and public-health procedures should not be assumed to replace national or European requirements. Medication authorisation and prescribing rules remain jurisdiction-specific.
UEMS European Board of Dermatovenereology Diploma Examination 2026 · Training Requirements for the Specialty of Dermatology and Venereology
This guide addresses the UEMS European Board of Dermatovenereology Diploma Examination, EBDVD, at postgraduate specialist level. Its independently authored questions and flashcards support learning and are not official UEMS items or pass predictions.
Outline used: Official 2026 examination page, reviewed 2026-10-10, with its linked curriculum approved 2017-10-21. No separate syllabus effective date is stated. The workbook's EBDV Diploma label maps to the issuer's EBDVD Examination; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Foundations20% (derived from published Session 1: 40/200 questions)
1.How does primary lesion morphology narrow a differential?
A primary lesion describes the process before scratching, infection or treatment alters it. A macule is flat, a papule is solid and raised, and a vesicle contains fluid; plaques describe broader palpable lesions. Secondary scale, crust and erosion describe subsequent surface change. Record the underlying lesion, its contents and its surface separately. This preserves diagnostic information when several diseases share the same colour or symptom.
Apply it
A patient describes itchy spots, but examination shows broad palpable lesions covered with dry scale. Describe scaly plaques and their distribution before selecting investigations; the patient's word spots does not distinguish an inflammatory plaque from a flat pigment change.
Common pitfall: Calling every red lesion a rash loses structural information. Crust describes dried exudate and cannot establish whether the original lesion was pustular, vesicular or eroded.
Training Requirements for the Specialty of Dermatology and Venereology
2.Why must distribution and skin colour accompany lesion description?
Distribution connects morphology to anatomy, exposure and disease behaviour. Symmetry, flexural or extensor predominance, mucosal involvement and a relationship to contact surfaces can change the differential even when individual lesions look similar. Visible erythema also varies with background pigmentation. Assess texture, swelling, scale and symptoms alongside colour, rather than requiring bright redness before recognising inflammation. Describe what is observed before assigning a diagnostic label.
Apply it
Two patients have facial papules, but one also reports central facial flushing and gritty eyes. Examine the distribution and ocular symptoms together; less visible redness in deeply pigmented skin should not remove rosacea from consideration.
Common pitfall: A colour-based shortcut can miss inflammation in darker skin. Conversely, distribution alone cannot confirm a diagnosis when lesion structure or symptoms disagree.
Training Requirements for the Specialty of Dermatology and Venereology · NIAMS: Rosacea
3.How should histopathological patterns be linked to clinical findings?
Histopathology describes tissue changes that must be interpreted with the clinical pattern and specimen site. The level of a blister, loss of keratinocyte adhesion and the distribution of inflammation provide different kinds of information. Pemphigus vulgaris, for example, shows suprabasal acantholysis rather than a subepidermal split. A useful interpretation integrates the microscopic pattern, lesion age, mucosal findings and immunopathology instead of treating an isolated descriptive term as a complete diagnosis.
Apply it
A pathology report describes suprabasal acantholysis in a patient with persistent oral erosions. Correlate this with pemphigus testing and examination findings; the combination is more informative than interpreting either oral ulceration or acantholysis alone.
Common pitfall: A microscopic pattern is not always disease-specific. Missing clinical information or an unsuitable specimen can make a technically accurate report insufficient for diagnosis.
EADV Updated S2K Guidelines for Pemphigus Vulgaris and Foliaceus, 2020
4.Why do histology and direct immunofluorescence require different specimens?
Routine histology examines tissue architecture, whereas direct immunofluorescence detects immunoglobulin or complement deposited in tissue. In suspected autoimmune blistering disease, these questions commonly require separate specimens and different handling. Formalin is appropriate for routine histology but is unsuitable for the standard direct immunofluorescence pathway. Agree transport arrangements with the laboratory, using its accepted immunofluorescence medium and delivery conditions. Correct sampling cannot compensate for incorrect preservation.
Apply it
Before biopsying an unexplained blistering eruption, prepare separate labelled containers for routine histology and immunofluorescence. Confirm the receiving laboratory's transport instructions first, so both tissue architecture and immune deposits remain assessable after delivery.
Common pitfall: Putting both specimens into formalin is convenient but can compromise immunofluorescence. An uninterpretable immune study should not be mistaken for evidence against autoimmune disease.
EADV Updated S2K Guidelines for Bullous Pemphigoid, 2022 · EADV Updated S2K Guidelines for Pemphigus Vulgaris and Foliaceus, 2020
5.Which denominator distinguishes incidence from prevalence?
Incidence measures new cases arising in a population at risk over a specified interval; an incidence rate uses person-time. Prevalence measures existing cases in a defined population at a particular time or during a specified period. A chronic disease can have substantial prevalence despite modest incidence because affected people remain cases for years. Choose the measure that matches the question: disease onset, current service burden or change over time.
Apply it
A dermatology registry records 80 newly diagnosed cases during a year and 600 people living with the condition on a census date. Use new cases for incidence calculations and existing cases for prevalence, with the appropriate population denominator.
Common pitfall: The number attending a specialist clinic is not automatically population prevalence. Referral patterns and access can change clinic counts without changing underlying disease frequency.
Training Requirements for the Specialty of Dermatology and Venereology
6.How does pretest probability change a positive test's meaning?
Sensitivity and specificity describe test performance conditional on disease status; positive predictive value asks how often a positive result represents disease in the tested population. When pretest probability is low, false positives may form a substantial share of positive results. Clinical history and exposure therefore matter before and after testing. Low-positive HSV-2 antibody results illustrate why an apparently positive laboratory label may require confirmation with a different method.
Apply it
An asymptomatic person with little exposure risk receives a low-positive HSV-2 antibody result. Discuss the possibility of a false positive and arrange appropriate confirmation rather than presenting an unconfirmed screening result as a definite lifelong diagnosis.
Common pitfall: High sensitivity does not make every positive result true. Predictive value depends on disease probability as well as the assay's sensitivity and specificity.
CDC STI Treatment Guidelines: Genital Herpes · Training Requirements for the Specialty of Dermatology and Venereology
7.How do prevention and early detection address different cancer risks?
Prevention aims to reduce disease occurrence, whereas early detection identifies disease already developing. Ultraviolet exposure is a modifiable melanoma risk factor; personal history, family history and multiple naevi also inform risk assessment. Recognition of a changing lesion addresses a different decision from reducing future exposure. Candidates should connect the intervention to its intended outcome and avoid interpreting detection of more lesions as proof that underlying disease incidence has fallen.
Apply it
A patient with many naevi asks whether monitoring makes sun protection unnecessary. Explain that surveillance seeks suspicious changes, while reducing ultraviolet exposure addresses a modifiable risk; the two strategies serve complementary purposes in ongoing care.
Common pitfall: A reassuring examination today does not remove future risk. Equally, a risk factor does not establish that an individual changing lesion is malignant.
8.What connects COL7A1 to dystrophic epidermolysis bullosa?
COL7A1 encodes type VII collagen, a principal component of anchoring fibrils that stabilise attachment between epidermis and dermis. Abnormal or deficient type VII collagen weakens this attachment, allowing minor friction to produce blistering. Healing can leave scars, distinguishing the clinical problem from a purely transient surface injury. The mechanism links a structural protein defect to skin fragility, while the amount and function of residual protein help explain variation in severity.
Apply it
A child has friction-induced blisters, abnormal nails and scars after healing. Consider an inherited attachment defect and pursue specialist diagnostic assessment; the history of recurrent mechanical fragility is more informative than treating each blister as an unrelated injury.
Common pitfall: Type VII collagen is an anchoring-fibril protein, not a desmosomal cadherin. Substituting desmoglein biology confuses inherited dystrophic epidermolysis bullosa with pemphigus.
9.How do dominant and recessive dystrophic epidermolysis bullosa differ?
Dystrophic epidermolysis bullosa can result from dominant or recessive COL7A1 variants, so the gene name alone does not establish recurrence risk. Recessive disease involves pathogenic variants affecting both gene copies; dominant disease can arise from one altered copy, including a new variant. Severe recessive disease can cause extensive scarring and systemic complications. Genetic counselling should integrate molecular findings and pedigree rather than infer inheritance from severity or family history alone.
Apply it
Unaffected parents have a child with molecularly confirmed recessive dystrophic epidermolysis bullosa. Explain the carrier mechanism and arrange family-specific counselling; absence of affected parents does not contradict a recessive diagnosis or eliminate recurrence concerns.
Common pitfall: A negative family history does not exclude inherited disease. Recessive inheritance and new dominant variants can both produce an affected child without an affected parent.
10.Which findings support alopecia areata rather than destructive hair loss?
Alopecia areata involves an immune attack on hair follicles and commonly produces sudden round or oval patches without visible scarring. Short hairs narrowing toward their base may occur at active edges. The absence of scar formation preserves the possibility of regrowth, although the course remains unpredictable. Alopecia totalis refers to loss of all or nearly all scalp hair; alopecia universalis extends to nearly all body hair as well.
Apply it
A patient develops a smooth circular scalp patch with short tapered hairs at its margin and no obvious scar. Consider alopecia areata, document other hair and nail involvement, and explain that regrowth and recurrence cannot be predicted with certainty.
Common pitfall: Alopecia totalis describes scalp involvement, not complete body-hair loss. Do not promise permanent recovery simply because the affected follicles have not been destroyed.
11.How do psoriasis variants change the expected surface appearance?
Psoriasis is an immune-mediated disorder in which inflammatory signalling accelerates epidermal cell production. Plaque disease commonly produces symmetrical raised lesions with scale on the scalp and extensor surfaces. Inverse psoriasis affects folds and may appear smooth rather than heavily scaly. Guttate disease produces numerous smaller lesions, often after an upper respiratory infection. Recognising variants prevents an overly narrow requirement for thick silvery scale in every anatomical setting.
Apply it
A patient with established extensor plaques develops smooth inflamed patches in the groin. Consider inverse psoriasis within the differential and assess the whole distribution rather than rejecting psoriasis because the fold lesions lack prominent scale.
Common pitfall: Pustules do not automatically prove bacterial infection, and absent scale in a moist fold does not exclude psoriasis. Morphology must be interpreted by site.
12.When should facial rosacea prompt assessment beyond the skin?
Rosacea can combine central facial flushing, persistent colour change, visible vessels, inflammatory papules and tissue thickening. Ocular involvement may cause grittiness, dryness, redness or eyelid inflammation and can threaten vision if untreated. Ask about eye symptoms even when the consultation concerns facial appearance. The relevant distinction is between a skin-limited complaint and disease affecting another organ, rather than assuming the intensity of facial redness predicts ocular importance.
Apply it
A patient seeking treatment for facial flushing mentions persistent gritty eyes and recurrent eyelid irritation. Assess possible ocular rosacea and arrange appropriate eye evaluation; improving the facial papules alone would leave an important manifestation unaddressed.
Common pitfall: Do not dismiss ocular symptoms as cosmetic discomfort. Conversely, facial redness has multiple causes, so rosacea requires a compatible overall clinical pattern.
Inflammatory and allergic disease20% (derived from published Session 2: 40/200 questions)
13.Why should psoriasis assessment include joints and entheses?
Psoriasis can accompany inflammatory arthritis affecting joints, the spine and entheses, where tendons or ligaments attach to bone. Persistent swelling, stiffness or Achilles-region pain should therefore change assessment beyond skin severity. Untreated psoriatic arthritis can cause irreversible damage. A patient with limited skin involvement may still have clinically important musculoskeletal disease, so the amount of visible psoriasis cannot determine whether joint symptoms deserve further evaluation.
Apply it
A patient whose plaques are controlled reports new finger swelling and prolonged stiffness after waking. Investigate inflammatory musculoskeletal disease and coordinate assessment rather than simply increasing topical treatment because the original diagnosis was dermatological.
Common pitfall: Attributing all joint pain to mechanical wear can delay recognition. Skin improvement does not demonstrate that associated inflammatory arthritis is absent or controlled.
14.What makes bullous pemphigoid a subepidermal blistering disease?
Bullous pemphigoid is an autoimmune disorder targeting basement-membrane-zone proteins, especially BP180 and BP230. Separation occurs beneath the epidermis, helping explain the characteristically tense blister roof. Marked itch and urticarial or eczematous lesions may precede obvious bullae, particularly in older adults. Clinical appearance suggests the diagnosis, but histology and immunopathology establish the relevant split and immune pattern rather than relying on age or blister tension alone.
Apply it
An older adult has weeks of severe itch followed by tense blisters on inflamed skin. Include bullous pemphigoid prominently and obtain appropriate tissue studies; the earlier eczematous phase does not make the later blistering unrelated.
Common pitfall: Absence of bullae early in the course does not exclude pemphigoid. A positive circulating antibody result also needs interpretation alongside clinical and tissue findings.
15.How should a suspected pemphigoid eruption be sampled?
For routine histology, a recent intact blister can demonstrate a subepidermal split and associated inflammation. Direct immunofluorescence uses suitable perilesional nonbullous skin and typically shows linear IgG and/or C3 along the dermoepidermal junction. These samples answer complementary questions: where tissue separates and where immune material is deposited. Select and preserve each specimen deliberately; a destroyed blister centre may lose the architecture needed for a useful immune study.
Apply it
A patient has one fresh tense blister and several excoriated erosions. Sample the fresh lesion for histology and suitable nearby nonbullous skin for direct immunofluorescence, sending each through its appropriate laboratory pathway.
Common pitfall: Biopsying only an old erosion can produce nonspecific damage. Linear basement-membrane staining also requires classification within the wider subepidermal autoimmune blistering differential.
16.Which desmoglein patterns distinguish major pemphigus phenotypes?
Pemphigus antibodies disrupt desmosomal adhesion between epithelial cells. Anti-desmoglein 3 is associated particularly with mucosal pemphigus vulgaris, while anti-desmoglein 1 accompanies pemphigus foliaceus and cutaneous involvement in mucocutaneous vulgaris. Desmoglein expression across tissues helps explain these phenotypes. Persistent painful oral erosions therefore fit vulgaris more readily than foliaceus. Antibody profiles support classification but must be matched with histology, immunofluorescence and the actual distribution of disease.
Apply it
A patient has persistent oral erosions and anti-desmoglein 3 antibodies, with little skin disease. Consider a mucosal pemphigus vulgaris phenotype and correlate with tissue findings rather than requiring widespread cutaneous blistering before recognising disease.
Common pitfall: Pemphigus foliaceus generally lacks mucosal involvement. Treating desmoglein 1 and desmoglein 3 as interchangeable loses a useful connection between antigen expression and phenotype.
EADV Updated S2K Guidelines for Pemphigus Vulgaris and Foliaceus, 2020
17.How do pemphigus histology and immunofluorescence differ from pemphigoid?
Pemphigus produces intraepidermal acantholysis: keratinocytes lose adhesion to neighbouring cells. The split is typically suprabasal in vulgaris and more superficial, near the granular layer, in foliaceus. Direct immunofluorescence shows epithelial cell-surface IgG and/or C3, contrasting with the linear basement-membrane-zone pattern of pemphigoid. Read the split level and immune location together, because either finding alone provides less reliable discrimination than their concordance.
Apply it
Flaccid blisters and oral erosions are accompanied by suprabasal acantholysis and intercellular IgG. Integrate these findings as a pemphigus pattern; a basement-membrane attachment disorder would not explain the combined microscopic and immune distribution.
Common pitfall: A positive Nikolsky phenomenon is not a complete diagnosis. It describes skin fragility and cannot substitute for identifying the split level and immunopathological pattern.
EADV Updated S2K Guidelines for Pemphigus Vulgaris and Foliaceus, 2020 · EADV Updated S2K Guidelines for Bullous Pemphigoid, 2022
18.What distinguishes irritant from allergic contact dermatitis?
Irritant contact dermatitis results from direct barrier injury and inflammation, whereas allergic contact dermatitis involves delayed hypersensitivity to a sensitising substance. Repeated wet work can contribute to irritant disease without a specific contact allergy. Patch testing investigates delayed contact sensitisation, but a result becomes diagnostically useful only when linked to exposure and clinical findings. The two mechanisms can coexist, particularly in occupational hand dermatitis with multiple exposures.
Apply it
A cleaner develops hand eczema during frequent washing and glove use. Assess cumulative irritation and potential glove or product allergens; identifying wet work does not exclude a superimposed delayed contact allergy contributing to persistence.
Common pitfall: A negative patch test does not prove the skin is healthy or exclude irritant dermatitis. A positive result does not automatically explain every eczematous site.
19.How is clinical relevance assigned to a positive patch test?
A positive patch test demonstrates contact sensitisation, not necessarily the cause of the current eruption. Current relevance requires sufficient exposure compatible with the patient's history and disease distribution. Past relevance describes an earlier attributable episode; unknown relevance means the link remains unestablished. Review work, home and recreational products and consider improvement with avoidance. Reaction strength alone does not determine whether the allergen explains the presenting dermatitis.
Apply it
A patient with hand eczema has a positive nickel test but no identified current nickel exposure. Record the sensitisation, investigate plausible sources and retain unknown relevance if necessary rather than declaring nickel the established cause of the hand disease.
Common pitfall: Unknown relevance is not synonymous with a false-positive result. Conversely, a strong reaction cannot replace evidence that the allergen reaches the affected skin.
20.When should patch tests be read, and what makes a reaction positive?
Patch testing assesses delayed T-cell-mediated hypersensitivity. At least two readings are recommended; ideally read on day 2, day 3 or 4, and day 7, counting application as day 0. Late readings detect reactions missed earlier, particularly with corticosteroids, gold, acrylates and aminoglycoside antibiotics. Inspect and palpate: faint erythema alone is doubtful (?+); erythema with infiltration, possibly papules, is weak positive (+). Papules and vesicles with infiltration support a stronger positive (++), while coalescing vesicles indicate an extreme reaction (+++). Clinical relevance remains a separate assessment.
Apply it
A corticosteroid test site shows faint redness on day 3 but develops palpable infiltration and papules by day 7. The late reading establishes positive morphology that the early doubtful appearance could not establish.
Common pitfall: A day-2-only reading can miss allergy. Neither itching nor faint redness alone establishes a positive reaction; doubtful findings may need further investigation.
21.When is urticaria classified as chronic spontaneous disease?
The 2026 international guideline classifies urticaria as chronic when wheals, angioedema or both recur for more than six weeks. Spontaneous disease lacks a definite eliciting factor; inducible disease has a reproducible subtype-specific trigger. The duration refers to the overall course, not persistence of an individual wheal. Separate those two timelines when taking the history, because a fixed lesion lasting unusually long may require reconsideration of the diagnosis.
Apply it
A patient reports eight weeks of migrating itchy wheals, each disappearing by the following day, without a reproducible physical trigger. Classify the course as chronic spontaneous urticaria while checking whether any features suggest an alternative disorder.
Common pitfall: Chronic does not mean that one wheal remains for six weeks. Confusing lesion duration with disease duration obscures an important diagnostic distinction.
22.Why does atopic eczema need both barrier care and control of inflammation?
Atopic eczema combines epidermal barrier dysfunction with inflammation. Increased transepidermal water loss produces dryness, while impaired barrier function facilitates penetration of irritants and allergens. Emollients supply hydration and lipids and reduce evaporation; frequent daily use supports the barrier and helps prevent flares. Active eczema also needs anti-inflammatory treatment. The [EuroGuiDerm atopic eczema guideline](https://www.guidelines.edf.one/guidelines/atopic-ezcema) recommends topical corticosteroids for acute flares and planned intermittent treatment of recurrent sites after control. Treatment assessment should include itch and sleep alongside visible lesions.
Apply it
An adolescent with established flexural eczema has dry skin and itchy inflamed plaques despite occasional moisturiser use. Institute regular emollients and treat the active inflammation, then consider proactive maintenance if the same sites repeatedly relapse.
Common pitfall: Emollients alone may leave active inflammation undertreated. A positive sensitisation test does not by itself establish that an allergen causes the eczema.
EDF Guidelines and Consensus Statements · Training Requirements for the Specialty of Dermatology and Venereology
23.Which treatment principle comes first in uncomplicated chronic urticaria?
A modern second-generation H1 antihistamine at its standard dose is first-line symptomatic treatment because histamine contributes to wheals and itch. In chronic spontaneous urticaria, regular treatment is preferred to symptom-triggered use. These agents generally cause fewer sedative and anticholinergic effects than first-generation antihistamines. If regular standard-dose treatment provides inadequate control, clinician-supervised escalation of one second-generation H1 antihistamine up to fourfold the standard dose is recommended. This up-dosing is off-label, and doses above fourfold are not recommended.
Apply it
For an untreated adult who drives for work, select an appropriate minimally sedating second-generation H1 antihistamine at its standard dose, taken regularly. Review adherence, symptom control and adverse effects before escalating. Persistent wheals despite an adequate regular standard-dose trial can justify supervised up-dosing of that single agent within the fourfold ceiling.
Common pitfall: Do not start at fourfold dosing simply because symptoms have lasted longer than six weeks. Explain the off-label status before up-dosing and assess individual sedation risk, especially for driving. Improvement with antihistamines does not establish an external allergy, and antihistamines do not replace emergency treatment of anaphylaxis.
24.Why does angioedema without wheals require a broader mechanism-based assessment?
Recurrent angioedema without wheals raises the possibility of bradykinin-mediated disease, although mast-cell-mediated swelling can also occur without wheals. Review medications, particularly ACE inhibitors, which impair bradykinin degradation. Family history, recurrent abdominal attacks and poor antihistamine response strengthen suspicion of a bradykinin mechanism but do not independently establish it. When C1-inhibitor-related angioedema is suspected, measure C4, C1-inhibitor concentration and C1-inhibitor function. Add C1q when acquired C1-inhibitor deficiency is suspected.
Apply it
For recurrent nonitchy lip swelling with little antihistamine benefit, check explicitly for ACE-inhibitor exposure and ask about relatives with similar attacks and episodes of abdominal pain. Request C4 and both quantitative and functional C1-inhibitor testing when the history suggests C1-inhibitor-related disease. Later onset without a family history should prompt consideration of acquired deficiency and C1q measurement. Tongue or throat swelling, voice change or stridor requires immediate emergency airway assessment; blood testing must not delay this.
Common pitfall: Absence of wheals is a discriminating clue, not proof of hereditary angioedema. Normal initial results do not exclude every hereditary subtype: hereditary angioedema with normal C1-inhibitor concentration and function exists. A convincing history therefore warrants specialist assessment even when the initial panel is normal.
Infections and sexual health20% (derived from published Session 3: 40/200 questions)
25.How do clinical findings and chronology establish syphilis stage?
Primary syphilis may produce a chancre, secondary disease can produce rash and mucocutaneous lesions, and latent infection lacks clinical manifestations. Under CDC terminology, early latent infection was acquired within the preceding year; other latent cases are late or of unknown duration. Stage depends on reliable history and examination, not antibody titre alone. A painless ulcer is characteristic but not obligatory, because primary lesions can be multiple, atypical or painful.
Apply it
An asymptomatic patient has confirmed syphilis serology but no previous tests, recognised symptoms or reliable acquisition date. Do not label the infection early solely because the RPR titre is high; classify duration using supported historical evidence.
Common pitfall: The CDC one-year early-latent convention should not be silently substituted for every jurisdiction's staging system. A high titre cannot independently date acquisition.
26.Which syphilis titre change is clinically significant?
A fourfold nontreponemal titre change equals two serial dilution steps and is considered clinically significant when the same test method is used. For example, RPR changing from 1:32 to 1:8 is a fourfold decline. RPR and VDRL titres are not directly interchangeable. Treponemal tests often remain reactive after treatment and should not be used as a numerical measure of treatment response or as proof of persistent active infection.
Apply it
A patient's RPR falls from 1:64 to 1:16 using the same laboratory method. Recognise a fourfold decline, then interpret it with stage, treatment history and follow-up timing rather than expecting the treponemal assay to become negative.
Common pitfall: A change from 1:16 to 1:8 is only twofold. Comparing an RPR result with a later VDRL result can create a misleading apparent trend.
27.When does an STI presentation require additional HIV assessment?
Offer HIV testing during STI assessment; CDC specifically recommends it for everyone with genital herpes. A recent exposure followed by fever and rash raises concern for acute HIV, although these findings are nonspecific. Under the [CDC HIV testing algorithm](https://www.cdc.gov/std/treatment-guidelines/hiv.htm), begin with a laboratory HIV-1/2 antigen–antibody assay and investigate reactive results with antibody differentiation testing. Request HIV RNA when acute infection is suspected despite negative or indeterminate initial testing, or when a reactive screen has a negative supplemental antibody result. Early infection can precede detectable antibodies.
Apply it
A patient develops fever and a widespread rash two weeks after a sexual exposure and has a negative rapid antibody test. Request laboratory antigen–antibody and HIV RNA testing rather than excluding acute HIV from the rapid result.
Common pitfall: A negative early antibody test does not exclude acute infection. If RNA is also negative but very early infection remains possible, arrange repeat testing; confirmed infection requires prompt linkage to HIV care.
CDC STI Treatment Guidelines: Genital Herpes · Training Requirements for the Specialty of Dermatology and Venereology
28.When do ocular symptoms change syphilis assessment?
Ocular syphilis can occur at any stage and can cause permanent visual loss. Reactive syphilis serology with eye symptoms requires a full ocular examination, including cranial nerve assessment. Neurological abnormalities influence the need for cerebrospinal fluid evaluation. CDC guidance states that confirmed isolated ocular abnormalities without cranial nerve dysfunction do not require CSF examination before treatment. The decisive issue is organ involvement, not whether a rash or chancre is currently present.
Apply it
A patient with reactive syphilis serology reports new blurred vision despite having no skin lesions. Arrange prompt ocular assessment and evaluate neurological findings; do not allow the absence of a classic secondary eruption to reduce concern.
Common pitfall: Latent-looking serology does not exclude ocular disease. Requiring every patient with confirmed isolated ocular involvement to undergo lumbar puncture first can delay appropriate care.
29.Which test best investigates an active genital herpes lesion?
Type-specific virological testing from an active lesion confirms suspected genital herpes. NAAT is highly sensitive and distinguishes HSV-1 from HSV-2, which informs recurrence and shedding counselling. Culture sensitivity falls as lesions heal, and a negative result from an older lesion does not reliably exclude infection. Blood PCR is not the routine diagnostic test for localised genital herpes. Match the specimen to the anatomical manifestation and stage of the lesion.
Apply it
A patient presents with a fresh painful genital vesicle after previous unconfirmed episodes. Obtain lesion material for type-specific HSV NAAT; a serum antibody result alone would not demonstrate which virus is causing the current lesion.
Common pitfall: A negative healing-lesion swab cannot conclusively exclude herpes. A Tzanck preparation also lacks the sensitivity and specificity needed for reliable type-specific confirmation.
30.Which anogenital findings suggest lichen sclerosus, and when is biopsy needed?
Lichen sclerosus is a noninfectious inflammatory disorder that can cause whitish sclerosis, fragile skin, fissures, purpura and progressive architectural loss. Vulval and perianal involvement may form a figure-of-eight distribution; penile disease may cause phimosis or meatal narrowing. The [EuroGuiDerm lichen sclerosus guideline](https://www.guidelines.edf.one/uploads/attachments/clmub3q4l0an5uhjrluc4r0yq-lichen-sclerosus-gl.pdf) supports clinical diagnosis in typical cases, with biopsy for uncertainty, treatment failure or suspected neoplasia. Potent or very potent topical corticosteroids, such as clobetasol propionate 0.05%, are first-line treatment. Follow-up addresses disease control, scarring and cancer warning signs.
Apply it
An adult has longstanding vulval itch, pallor, fissures and labial resorption despite repeated antifungal treatment. Assess lichen sclerosus; a persistent focal hyperkeratotic or eroded area requires assessment for neoplasia and targeted biopsy.
Common pitfall: Genital itch does not establish candidiasis. Symptom relief does not exclude persistent disease or neoplasia, and potency rules for ordinary flexural eczema should not displace disease-specific lichen sclerosus treatment.
EDF Guidelines and Consensus Statements · Training Requirements for the Specialty of Dermatology and Venereology
31.How does asymptomatic HSV shedding change prevention counselling?
HSV can be shed when no lesions are visible, so absence of an outbreak does not eliminate transmission risk. Genital HSV-2 generally recurs and sheds more often than genital HSV-1. Suppressive antiviral therapy can reduce recurrences and, in defined circumstances, transmission, but does not eradicate latent infection. Counselling should combine the infection's natural history with practical risk reduction rather than promise that symptom-based avoidance or medication makes transmission impossible.
Apply it
A patient with genital HSV-2 asks whether a symptom-free month means infection is no longer transmissible. Explain intermittent shedding and discuss partner communication, avoiding sex during symptoms and suitable preventive options without presenting any measure as complete protection.
Common pitfall: Antivirals suppress viral activity rather than cure latent infection. A normal examination cannot certify that genital shedding is absent on that day.
32.How should gonorrhoea sampling follow the sexual history?
Gonorrhoea can involve urethral, cervical, rectal and pharyngeal sites, including asymptomatic infection. Specimen selection should reflect reported exposure and the performance of the locally available assay. A urine result does not establish the infection status of every exposed mucosal site. Take an anatomy-based, nonjudgmental history so testing addresses the actual contact pattern rather than assumptions based on identity, symptoms or the presence of a single positive specimen.
Apply it
A patient reports receptive anal and oral exposure but no genital symptoms. Select appropriate rectal and pharyngeal testing according to local protocols; relying only on urine would leave relevant exposure sites unassessed despite an apparently complete STI visit.
Common pitfall: A negative urogenital test does not clear extragenital sites. Conversely, a positive result at one site does not prove that all other sites are infected.
CDC STI Treatment Guidelines: Gonococcal Infections Among Adolescents and Adults
33.Why is culture essential when gonorrhoea treatment failure is suspected?
Persistent gonorrhoea after recommended treatment requires distinction between reinfection and antimicrobial treatment failure. Review adherence, partner treatment and sexual re-exposure. When failure is credible and reinfection unlikely, obtain relevant specimens for culture and susceptibility testing, preferably with simultaneous NAAT, before retreatment. NAAT detects the organism's nucleic acid but does not provide a conventional phenotypic susceptibility result. Culture therefore adds information that repeating NAAT alone cannot supply.
Apply it
Symptoms persist after appropriate gonorrhoea treatment; the patient reports no subsequent sexual contact and partners were treated. Obtain culture from relevant sites for susceptibility testing and coordinate expert management rather than repeatedly ordering NAAT without investigating resistance.
Common pitfall: Persistent symptoms do not automatically prove resistance, because reinfection and other causes are possible. However, assuming reinfection without assessment can miss a genuine treatment failure.
CDC STI Treatment Guidelines: Gonococcal Infections Among Adolescents and Adults
34.What constitutes direct evidence of scabies infestation?
Scabies diagnosis is supported by identifying mites, eggs or faecal material in appropriate skin samples or by suitable visual diagnostic methods. Compatible itch, burrows and contact history strengthen suspicion, but clinical features overlap with eczema and other pruritic disorders. Sampling a likely burrow is more informative than scraping an arbitrary excoriation. Failure to demonstrate a mite does not automatically exclude disease when sampling sensitivity and the clinical context are considered.
Apply it
Several household members develop itch, and one has a suspected finger-web burrow. Examine and sample the most informative site using available diagnostic methods rather than treating an isolated negative scraping from a nonspecific scratched area as definitive exclusion.
Common pitfall: Itch alone is not direct proof of infestation. Conversely, a negative specimen can reflect site selection or low organism burden rather than absence of scabies.
35.Why does crusted scabies require different clinical concern?
Crusted scabies can occur in people with impaired immune function or other vulnerabilities and carries a very large mite burden. Extensive hyperkeratotic or crusted lesions may be more prominent than the classic picture of intensely itchy sparse burrows. The organism burden increases transmission concern and changes management complexity. Recognise the phenotype early, assess contacts and infection-control needs, and distinguish it from ordinary eczema or psoriasis before escalating immunosuppressive treatment.
Apply it
An immunosuppressed patient develops widespread thick crusts, and carers report new itch. Consider crusted scabies and arrange prompt diagnostic and infection-control assessment rather than interpreting the patient's limited itch as evidence against an infestation.
Common pitfall: Severe infestation does not always produce proportionately severe itch. Treating unexplained crusting as inflammatory disease without considering scabies can increase transmission and worsen the clinical problem.
36.How do direct mycology and fungal culture answer different questions?
Direct examination of suitable skin, hair or nail material can demonstrate fungal structures, while culture may help identify the causative organism. Potassium hydroxide preparation clears keratin to improve visualisation. Interpretation depends on specimen quality, the affected tissue and concordance with the clinical pattern. These are complementary diagnostic techniques rather than interchangeable labels. The curriculum explicitly includes both direct mycological examination and culture interpretation as specialist competencies.
Apply it
A patient has a dystrophic nail with several possible causes. Obtain appropriate nail material for mycological assessment and interpret direct examination and culture alongside morphology rather than declaring every thickened nail to be fungal disease.
Common pitfall: Nail dystrophy is not synonymous with onychomycosis. A laboratory finding should be interpreted with the specimen's quality and the possibility of contamination or an alternative diagnosis.
Training Requirements for the Specialty of Dermatology and Venereology
Skin oncology and dermoscopy20% (derived from published Session 4: 40/200 questions)
37.Which dermoscopic structures increase concern in a melanocytic lesion?
An atypical pigment network has prominent, broad or dark lines with irregular arrangement. Streaks are peripheral radial linear or bulbous extensions; asymmetric distribution is concerning. Irregular dots or globules are round pigmented structures with uneven distribution. White scar-like areas and blue-grey peppering are regression structures, reflecting fibrosis and pigment-laden macrophages. These [pattern-analysis features](https://jamanetwork.com/journals/jamadermatology/fullarticle/189703) increase suspicion when combined in a changing lesion, but also occur in benign lesions. Integrate the whole pattern, evolution and clinical context; histology establishes diagnosis.
Apply it
A changing lesion has a broad irregular network, streaks confined to one edge and white areas with peppering. Arrange histological assessment, preferably complete full-thickness diagnostic excision where feasible.
Common pitfall: Regression does not prove benign resolution or melanoma. Small diameter and partial symmetry cannot override a concerning combination of structures and evolution.
NCI: Melanoma Treatment PDQ, Health Professional Version · Training Requirements for the Specialty of Dermatology and Venereology
38.Why should a melanoma biopsy preserve complete depth?
Melanoma diagnosis and microstaging require tissue that permits assessment of the lesion and its deepest invasion. Complete excisional biopsy is preferred where feasible for a suspicious lesion. A superficial or destructive procedure can prevent reliable thickness measurement and complicate subsequent decisions. Diagnostic removal and definitive wide excision serve different purposes: the first establishes pathology, while the second is planned using the resulting tumour information and anatomical context.
Apply it
A changing pigmented lesion on the trunk can be completely removed diagnostically. Choose an appropriate excisional biopsy that preserves depth rather than superficial destruction, so pathology can establish invasion and guide subsequent staging and definitive treatment.
Common pitfall: Removing visible pigment is not the same as obtaining a staging-quality specimen. A transected invasive base can leave the true Breslow thickness uncertain.
NCI: Melanoma Treatment PDQ, Health Professional Version · European Melanoma Guideline, Part 1: Diagnostics, Update 2024, Published 2025
39.What distinguishes Breslow thickness from surface diameter?
Breslow thickness measures vertical invasive melanoma depth histologically, whereas diameter measures horizontal surface extent. These quantities answer different questions and are not interchangeable. Primary tumour categorisation uses thickness together with ulceration, so a narrow lesion can still have substantial invasive depth. A pathology report must be read for these staging variables rather than replaced by a ruler measurement, a photograph or the apparent size of the pigmented surface.
Apply it
A lesion only a few millimetres across proves deeply invasive on pathology. Base primary tumour assessment on the reported Breslow thickness and ulceration rather than concluding that a small surface diameter necessarily means an early tumour category.
Common pitfall: Clinical diameter cannot substitute for histological depth. Likewise, a broad in situ lesion does not become invasive merely because it covers a large surface area.
40.Which thickness and ulceration findings define melanoma T1a and T1b?
Under AJCC eighth-edition criteria reproduced by NCI, T1a is an invasive melanoma below 0.8 mm without ulceration. T1b includes a tumour below 0.8 mm with ulceration, or one measuring 0.8–1.0 mm with or without ulceration. Apply both variables rather than thickness alone. T category describes the primary tumour; it does not establish the complete stage without regional and distant disease information and the appropriate clinical or pathological staging framework.
Apply it
An invasive melanoma measures 0.7 mm and has histological ulceration. Classify the primary as T1b despite its thickness being below 0.8 mm, then assess the additional information needed for the patient's complete staging.
Common pitfall: Do not classify every melanoma below 0.8 mm as T1a. Ulceration changes the category, and the primary T label is not the complete stage.
41.Who should be considered for melanoma sentinel lymph node biopsy?
Sentinel lymph node biopsy detects occult regional metastasis and supplies staging and prognostic information. The [ESMO guideline](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618628/) does not recommend it routinely for pT1a: below 0.8 mm without ulceration. Discuss it for pT1b: 0.8–1.0 mm, or below 0.8 mm with ulceration. It is recommended for clinically node-negative tumours exceeding 1.0 mm. Selected pT1a exceptions include high mitotic activity, a positive deep margin or unreliable thickness. Individual decisions consider comorbidity, preferences and whether staging will affect management.
Apply it
A completely sampled 0.6-mm nonulcerated tumour generally does not need routine SLNB. At 0.7 mm with ulceration, discuss SLNB; at 1.4 mm with clinically negative nodes, recommend it unless individual circumstances justify another decision.
Common pitfall: A suspicious palpable node needs direct diagnostic assessment rather than routine occult-node staging. Negative SLNB cannot exclude every metastatic site or eliminate recurrence risk.
42.How do in-transit melanoma deposits differ from distant metastases?
Melanoma staging distinguishes regional non-nodal disease, including satellites, microsatellites and in-transit metastases, from distant metastatic disease. Regional cutaneous or subcutaneous deposits can affect the N category even without an involved regional lymph node. Their location and relationship to the primary and drainage basin therefore matter. Do not assume that every separate skin deposit automatically means stage IV, or that regional disease requires a positive lymph node.
Apply it
After melanoma excision, a patient develops confirmed dermal melanoma deposits along the route toward the regional nodal basin, with no distant disease identified. Assess these as regional non-nodal spread rather than assigning distant metastasis solely because lesions are separate.
Common pitfall: Separate skin lesions require anatomical classification, not an automatic distant-stage label. A negative regional node assessment also does not erase documented in-transit disease.
43.How does a BRAF V600 alteration change melanoma systemic-treatment options?
BRAF V600 alterations can constitutively activate the RAF–MEK–ERK signalling pathway. In advanced melanoma with an eligible variant such as V600E, combined BRAF and MEK inhibition, for example dabrafenib plus trametinib, blocks successive pathway components. Eligibility depends on the exact variant, treatment setting and regimen; an unspecified BRAF alteration is insufficient. Immune checkpoint treatments act through immune regulation and remain options without a BRAF V600 mutation. The [ESMO guideline](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618628/) integrates mutation testing with stage and treatment selection.
Apply it
For unresectable metastatic V600E melanoma, discuss BRAF–MEK therapy alongside immunotherapy. The mutation expands treatment options but does not automatically determine which strategy should be used first.
Common pitfall: Do not generalise evidence for V600E to every BRAF variant or from metastatic to adjuvant treatment. Mutation status does not establish Breslow thickness or disease extent.
NCI: Melanoma Treatment PDQ, Health Professional Version · European Melanoma Guideline, Part 1: Diagnostics, Update 2024, Published 2025
44.How do basal and squamous cell carcinomas differ in behaviour?
Basal cell carcinoma is predominantly a locally invasive malignancy, while cutaneous squamous cell carcinoma has a more consequential capacity for regional and distant spread. Both can cause substantial local tissue destruction, so low metastatic potential does not make a basal cell carcinoma harmless. Histology, anatomical location, recurrence and other risk features guide management. Distinguish the tumour type before applying assumptions about surveillance, surgical planning or the significance of a regional node.
Apply it
A patient delays assessment of an enlarging facial lesion because basal cell carcinomas rarely metastasise. Explain that progressive local invasion can still damage important structures and require more complex treatment even without distant dissemination.
Common pitfall: Rare metastasis does not mean negligible morbidity. Conversely, not every cutaneous squamous cell carcinoma carries the same metastatic risk; individual tumour features matter.
45.Which findings increase concern in cutaneous squamous cell carcinoma?
Cutaneous squamous cell carcinoma risk assessment considers more than surface size. Poor differentiation, deeper invasion, perineural involvement, recurrence and certain anatomical locations can increase concern and affect treatment planning. A small tumour near a critical structure may require more careful margin control than its diameter suggests. Read the pathology and clinical history together, and distinguish local clearance from assessment of regional disease when high-risk features are present.
Apply it
A small recurrent squamous cell carcinoma on the ear shows perineural invasion. Treat recurrence, location and nerve involvement as meaningful risk features rather than selecting a low-intensity approach solely because the visible lesion is small.
Common pitfall: A single reassuring feature cannot cancel adverse pathology. Margin clearance addresses local disease but does not automatically resolve every question about regional risk or follow-up.
46.When does Mohs surgery offer a useful margin-control advantage?
Mohs surgery removes tumour in stages with microscopic examination of margins, aiming to achieve clearance while conserving uninvolved tissue. It is particularly useful for selected recurrent tumours, poorly defined borders and anatomically sensitive locations. Its value lies in controlled removal of contiguous local disease, not in treating every metastatic risk. Choose it because tumour behaviour and anatomy justify detailed margin assessment rather than because every skin cancer requires the same procedure.
Apply it
A recurrent basal cell carcinoma has indistinct borders near the eyelid. Consider Mohs surgery because clearance and tissue preservation are both important; a procedure that destroys tissue without margin assessment would answer the local-control question less reliably.
Common pitfall: Mohs is not a substitute for systemic staging when indicated. Histologically clear local margins also cannot exclude noncontiguous deposits or disease elsewhere.
47.What separates squamous cell carcinoma in situ from invasive disease?
Carcinoma in situ remains confined to the epithelial compartment, whereas invasive squamous cell carcinoma extends beyond that boundary into underlying tissue. This anatomical distinction changes biological implications and treatment assessment. Clinical scale, redness or plaque thickness cannot alone establish whether invasion is present. Histological evaluation must answer the depth question when it affects management, and a limited sample may not represent the most invasive portion of a heterogeneous lesion.
Apply it
A persistent scaly plaque contains a newly firm focal area. Ensure assessment addresses possible invasion rather than assuming that a previous superficial in situ diagnosis necessarily describes every part of the lesion at the current visit.
Common pitfall: In situ does not mean benign, and surface appearance cannot reliably exclude invasion. A partial specimen may leave uncertainty about unsampled areas of the lesion.
48.Why does melanoma follow-up assess more than local recurrence?
Melanoma follow-up considers recurrence, new primary lesions and the consequences of previous treatment. A healed excision site answers only a local question; it does not exclude regional, distant or separate primary disease. Risk and previous disease extent influence the surveillance approach. Persistent or new findings should be evaluated on their own merits rather than dismissed because an earlier tumour was removed with clear margins or because a long symptom-free interval has passed.
Apply it
A melanoma survivor has a normal scar but notices a new changing lesion elsewhere. Assess the new lesion independently and review the wider surveillance context rather than treating a reassuring scar examination as a complete cancer assessment.
Common pitfall: Clear original margins do not prevent a new primary melanoma. A long interval reduces some recurrence concerns but does not make every subsequent finding irrelevant.
Treatment, vascular disease and psychosomatics20% (derived from published Session 5: 40/200 questions)
49.Why is weekly methotrexate scheduling a critical safety distinction?
For psoriasis, oral methotrexate is prescribed on a weekly schedule, and accidental daily administration can cause fatal toxicity. The safety issue is the interval as well as the tablet strength or total amount. Confirm a named weekly day, a clear prescription and the patient's understanding when treatment begins or changes. Methotrexate also has oncology regimens, so assumptions from another indication must not be transferred to a dermatological prescription.
Apply it
A patient collecting methotrexate for psoriasis says the new label instructs daily use. Withhold further doses pending urgent clarification and assess whether any have already been taken; correcting the label alone would not address a possible overdose.
Common pitfall: A familiar tablet strength does not make an incorrect interval safe. Never infer a psoriasis schedule from an oncology regimen or an ambiguous medication list.
DailyMed: Methotrexate Tablets, Prescribing Information Revised May 2026
50.How does renal impairment increase methotrexate toxicity risk?
Methotrexate elimination is reduced in renal impairment, increasing exposure and the risk of adverse reactions. An unchanged prescribed weekly amount can therefore become unsafe when renal function deteriorates. Review current renal function, concurrent medicines and toxicity symptoms rather than relying on past tolerance. The prescribing information supports closer monitoring and dose reduction or discontinuation as appropriate; a stable historical prescription does not establish safety during a new illness.
Apply it
A patient previously stable on weekly methotrexate develops an acute decline in renal function and painful mouth ulcers. Suspect increased exposure and toxicity, arrange urgent assessment and review treatment instead of automatically renewing the established prescription.
Common pitfall: Previous tolerance cannot compensate for reduced clearance. Do not assume that toxicity requires either a deliberate dose increase or an obvious daily-versus-weekly error.
DailyMed: Methotrexate Tablets, Prescribing Information Revised May 2026
51.When does pregnancy potential change methotrexate prescribing?
Methotrexate can cause embryo-fetal toxicity and is contraindicated during pregnancy for non-neoplastic indications. Before dermatological treatment, assess pregnancy status and reproductive plans and provide effective contraception counselling consistent with the applicable product information. This is a treatment-selection issue, not simply an extra monitoring test after prescribing. Separate dermatological use from exceptional oncology contexts, because a medicine's use in one setting does not establish acceptability in another.
Apply it
A patient with psoriasis is considering pregnancy while discussing systemic treatment. Address reproductive plans before choosing methotrexate and select a suitable management strategy; routine blood monitoring would not remove the medicine's embryo-fetal risk.
Common pitfall: Folate supplementation does not make methotrexate safe in pregnancy. Avoid treating oncology exceptions or normal baseline laboratory results as permission for routine dermatological exposure.
DailyMed: Methotrexate Tablets, Prescribing Information Revised May 2026
52.What distinguishes PUVA from narrowband UVB?
PUVA combines a psoralen photosensitiser with ultraviolet A exposure. In topical PUVA, psoralen is applied locally, such as by a soak or bath, before UVA treatment. Narrowband UVB uses a different ultraviolet spectrum and does not require psoralen. These distinctions affect preparation, protection and counselling. Knowing that both are phototherapy is insufficient: identify the sensitiser, wavelength and treated area before applying one modality's instructions to another.
Apply it
A patient moves from narrowband UVB to hand-and-foot topical PUVA and asks whether preparation is identical. Explain the added psoralen exposure and review the new treatment-specific protection instructions rather than simply reusing the previous phototherapy routine.
Common pitfall: PUVA is not psoralen plus UVB, and topical psoralen is not interchangeable with oral administration. Route and spectrum change the relevant precautions.
British Association of Dermatologists: Phototherapy—Topical PUVA
53.How should topical anti-inflammatory treatment differ between eyelid and thick body eczema?
Choose corticosteroid potency and formulation by site, age and severity. For eyelid or fold eczema, use an appropriately brief mild-to-moderate corticosteroid course; a thick body plaque may need a stronger preparation. Calcineurin inhibitors such as tacrolimus suppress T-cell activation without causing skin atrophy, making them useful at sensitive recurrent sites. Explain transient burning. The [EuroGuiDerm topical-treatment recommendations](https://www.guidelines.edf.one/guidelines/atopic-ezcema) support planned intermittent maintenance after control.
Apply it
An adult using a potent body steroid repeatedly on eyelids needs a separate site-specific plan: control the flare, consider a calcineurin inhibitor for recurrence and continue emollients.
Common pitfall: An unchanged tube strength is not a universal prescription for every site. Prolonged inappropriate potent steroid use can cause thinning and telangiectasia; inadequate treatment also prolongs disease.
EDF Guidelines and Consensus Statements · Training Requirements for the Specialty of Dermatology and Venereology
54.How is the ankle–brachial pressure index calculated and interpreted?
Calculate an ankle–brachial pressure index (ABPI) separately for each leg. For that leg, divide the higher dorsalis pedis or posterior tibial systolic pressure by the higher brachial systolic pressure measured in either arm. Do not average the pedal pressures or use the arm on the same side automatically. A low ABPI indicates impaired arterial perfusion. Interpret the ratio together with absolute ankle pressure, symptoms and vascular examination before selecting compression. Under ESVS recommendations for active venous ulceration, sustained compression is not recommended when ankle pressure is below 60 mmHg, toe pressure is below 30 mmHg or ABPI is below 0.6.
Apply it
If brachial pressures are 110 and 120 mmHg, and the affected leg has dorsalis pedis pressure 60 mmHg and posterior tibial pressure 66 mmHg, its ABPI is 66/120 = 0.55. The ankle pressure exceeds 60 mmHg, but the ABPI remains below 0.6; this still excludes routine sustained compression and warrants arterial assessment.
Common pitfall: Medial arterial calcification, particularly in diabetes or chronic kidney disease, can make ankle arteries resist cuff compression. The measured occlusion pressure and ABPI may therefore be misleadingly high despite arterial disease. Obtain toe pressure and a toe–brachial index when ankle arteries are noncompressible or results conflict with clinical findings; digital arteries are generally less affected by this calcification. A high, unreliable ABPI does not establish adequate perfusion.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
55.Which perfusion findings make sustained ulcer compression unsafe?
The ESVS guideline advises against sustained compression for active venous ulceration when ankle pressure is below 60 mmHg, toe pressure below 30 mmHg or ABPI below 0.6. These findings indicate an arterial supply problem that compression could aggravate. Mixed disease above these boundaries still requires individual assessment and supervision. The thresholds identify important safety limits; they should not be misread as automatic approval for unrestricted compression whenever one value is higher.
Apply it
A patient with gaiter-region ulceration has ankle pressure 54 mmHg despite oedema and varicosities. Avoid sustained compression and obtain arterial assessment; a convincing venous component does not negate the danger indicated by the low absolute pressure.
Common pitfall: Checking ABPI alone can miss an unsafe absolute pressure. Passing a minimum threshold also does not remove the need to assess mixed disease and symptoms.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
56.What does venous duplex add to examination of an ulcerated leg?
Venous duplex assesses anatomy and blood flow, helping identify reflux, obstruction and the venous segments involved. Visible varicosities and oedema suggest venous disease but do not provide a complete haemodynamic map. Duplex findings can connect symptoms and ulceration with a treatable venous abnormality and guide intervention planning. It answers a different question from arterial pressure assessment, so a venous scan does not establish that compression is safe for the arterial circulation.
Apply it
A patient has recurrent ulceration despite conservative care and prominent superficial veins. Obtain an appropriate venous duplex assessment to define reflux or obstruction before planning intervention, while separately evaluating arterial perfusion relevant to compression.
Common pitfall: Visible veins do not identify every diseased segment. A normal arterial pressure assessment likewise cannot determine whether superficial reflux or deep venous obstruction is present.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
57.Why does venous ulcer care need treatment of venous hypertension?
Venous reflux or obstruction can sustain venous hypertension, contributing to oedema, inflammatory skin change and ulceration. Dressings manage the wound environment but do not by themselves correct the haemodynamic driver. Where arterial supply permits, compression supports healing; assessment of venous pathology may identify an additional intervention. Connect wound care with its cause rather than repeatedly changing surface products while persistent pressure-related disease remains unaddressed beneath the ulcer.
Apply it
A gaiter ulcer repeatedly improves and deteriorates while dressings are changed, but oedema remains substantial. Reassess perfusion, compression delivery and venous pathology rather than assuming another dressing brand will resolve the underlying healing problem.
Common pitfall: A clean wound bed does not prove the cause has been treated. Compression also requires perfusion assessment and cannot be applied indiscriminately to every leg ulcer.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
58.When can superficial venous intervention complement ulcer compression?
In suitable patients with venous ulceration and superficial venous incompetence, treating reflux can complement compression rather than serve only a cosmetic purpose. Duplex defines the relevant abnormality and helps determine an appropriate procedural strategy. Assessment must consider the wider venous system, arterial perfusion and patient suitability. A visible vein alone is insufficient justification, but documented pathological reflux can identify a haemodynamic target relevant to healing and recurrence prevention.
Apply it
A patient with an active venous ulcer has adequate arterial perfusion and duplex-confirmed superficial reflux. Discuss timely specialist assessment for reflux treatment alongside compression rather than waiting automatically for repeated ulcer recurrences before considering the underlying venous abnormality.
Common pitfall: Ablation is not selected from appearance alone. Do not assume that every superficial vein is expendable without understanding reflux, obstruction and the wider venous drainage.
ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
59.How should clinicians engage a patient with suspected delusional infestation?
Effective engagement acknowledges distress, examines the skin and considers submitted material without affirming an unsubstantiated infestation. A respectful therapeutic relationship makes further assessment and integrated care more achievable. Explore symptoms and impact, explain findings clearly and avoid confrontational arguments over the belief. Dermatological care remains important because scratching, chemicals or other attempted eradication methods may cause real injury even when an infestation is not demonstrated.
Apply it
A patient brings fibres believed to be parasites and has excoriated skin. Examine the material and lesions, acknowledge the suffering and explain the assessment plan while avoiding either confirmation of parasites or a dismissive confrontation.
Common pitfall: Repeated empiric antiparasitic treatment can reinforce an unsupported explanation. Abruptly declaring that nothing is wrong can also damage engagement despite genuine distress and skin injury.
British Association of Dermatologists Guidelines for Adults with Delusional Infestation, 2022
60.Why must secondary causes be assessed before diagnosing primary delusional infestation?
Delusional infestation may be primary or associated with another medical, psychiatric, medication-related or substance-related condition. A full history therefore includes symptom onset, mental health, medical illness, medicines, substance use and psychosocial context, with examination and targeted investigation. This avoids premature diagnostic closure and can identify a modifiable contributor. The presence of a fixed infestation belief does not remove the need to assess actual infestation, neurological symptoms or other physical explanations.
Apply it
A patient develops crawling sensations and a fixed infestation belief after a change in substance use. Investigate the temporal relationship and relevant medical and psychiatric factors before concluding that this is primary delusional infestation requiring an identical pathway to every other case.
Common pitfall: A characteristic belief does not establish a primary disorder. Conversely, identifying a secondary contributor does not make the patient's distress or associated skin damage unimportant.
British Association of Dermatologists Guidelines for Adults with Delusional Infestation, 2022
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give each published session sustained attention: its derived allocation is 20%, and the stated passing requirement applies separately to every session.
- Translate clinical images into lesion structure, distribution and discriminating findings before naming a diagnosis.
- Practise choosing specimen site, preservation and laboratory method together, especially for blistering disease, genital ulcers and suspected antimicrobial failure.
- Separate diagnostic evidence, disease staging, predictive biomarkers and treatment selection in oncology.
- Explain the mechanisms behind major safety boundaries: weekly methotrexate, reduced renal clearance, photosensitisation and arterial limits to compression.
- Extend revision beyond these 60 concepts using the full official outline, especially paediatric disease, systemic manifestations, HIV complications, other mucosal disorders, procedures and broader therapeutics.
A practical preparation plan
1. Map the full curriculum
Create a revision map using the five examination sessions and the linked specialty curriculum. Mark which competencies these concepts cover and identify the remaining conditions, investigations and procedures that need separate study.
2. Practise image-to-decision reasoning
For clinical slides and dermoscopic images, state morphology, distribution and the strongest discriminating cue. Then choose the next diagnostic or management decision and explain which alternative finding would change it.
3. Rehearse laboratory interpretation
Work through paired histology and immunofluorescence specimens, syphilis dilution changes, HSV assay limitations and gonorrhoea culture indications. Explain what each test can establish and what remains unresolved.
4. Build treatment safety explanations
Use brief cases to explain why renal decline changes methotrexate exposure, why psoralen changes ultraviolet precautions and why a venous ulcer still needs arterial assessment. Learn the causal reasoning alongside thresholds.
5. Use the drills diagnostically
Complete the 20 questions without looking at explanations. Review each distractor and record whether the error arose from recognition, mechanism, test interpretation or decision-making. Revisit the relevant domain with the flashcards.
6. Practise the published session pace
Use separately sourced learning material to practise blocks of 40 questions in 60 minutes, including image interpretation. Review performance by session rather than relying on an aggregate percentage from a short practice set.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- UEMS European Board of Dermatovenereology Diploma Examination 2026
- Training Requirements for the Specialty of Dermatology and Venereology
- UEMS Body Report 2026.1
- NIAMS: Psoriasis
- NIAMS: Alopecia Areata
- NIAMS: Rosacea
- MedlinePlus Genetics: Dystrophic Epidermolysis Bullosa
- EADV Updated S2K Guidelines for Bullous Pemphigoid, 2022
- EADV Updated S2K Guidelines for Pemphigus Vulgaris and Foliaceus, 2020
- ESCD Guideline for Diagnostic Patch Testing: Update 2026
- EDF Guidelines and Consensus Statements
- International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria, 2026
- CDC STI Treatment Guidelines: Syphilis
- CDC STI Treatment Guidelines: Genital Herpes
- CDC STI Treatment Guidelines: Gonococcal Infections Among Adolescents and Adults
- CDC STI Treatment Guidelines: Ectoparasitic Infections
- NCI: Melanoma Treatment PDQ, Health Professional Version
- NCI: Skin Cancer Treatment PDQ, Health Professional Version
- European Melanoma Guideline, Part 1: Diagnostics, Update 2024, Published 2025
- DailyMed: Methotrexate Tablets, Prescribing Information Revised May 2026
- British Association of Dermatologists: Phototherapy—Topical PUVA
- ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs
- British Association of Dermatologists Guidelines for Adults with Delusional Infestation, 2022
- Principles of Epidemiology | Lesson 3 - Section 2
- ILDS-Glossary-Cutaneous-Lesions.pdf
- Living EuroGuiDerm Guideline for the systemic treatment of Atopic Eczema | EDFG
- cl485y15k009csjjnxy8fr36v-6-basic-emollients-jun-2022.pdf
- cl485ybhe009usjjnyfz3u0zk-7-antiinflammatory-treatment-jun-2022.pdf
- clmub3q4l0an5uhjrluc4r0yq-lichen-sclerosus-gl.pdf
- Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests - Guidance for Industry and FDA Staff | FDA
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.